Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Zymeworks Inc.

< Previous 1 2 3 4 Next >
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks To Host Second Quarter 2023 Results Conference Call
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conference
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Appoints New Director
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks To Host First Quarter 2023 Results Conference Call
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conference
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks to Transfer Stock Listing to Nasdaq
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conference
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.